Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
作者信息
Saultier Paul, Ninove Laetitia, Szepetowski Sarah, Veneziano Mathilde, Visentin Sandrine, Barlogis Vincent, Saba Villarroel Paola Mariela, Amroun Abdennour, Loosveld Marie, de Lamballerie Xavier, Chambost Hervé
机构信息
Department of Pediatric Hematology, Immunology, and Oncology, APHM, La Timone Children's Hospital, Marseille, France.
Aix Marseille Univ, INSERM, INRAe, C2VN, Marseille, France.
出版信息
Br J Haematol. 2022 Jan;196(1):e1-e3. doi: 10.1111/bjh.17756. Epub 2021 Aug 1.
Abstract
摘要
相似文献
1
Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
Br J Haematol. 2022 Jan;196(1):e1-e3. doi: 10.1111/bjh.17756. Epub 2021 Aug 1.
2
COVID-19 Updates: Monoclonal Antibodies for COVID-19.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.
3
Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.
Biomed Res Int. 2024 Aug 6;2024:8182887. doi: 10.1155/2024/8182887. eCollection 2024.
4
Regdanvimab: First Approval.
Drugs. 2021 Dec;81(18):2133-2137. doi: 10.1007/s40265-021-01626-7.
5
Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients.
Pediatr Infect Dis J. 2021 Dec 1;40(12):e507-e509. doi: 10.1097/INF.0000000000003263.
6
Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
Obstet Gynecol. 2021 Dec 1;138(6):937-939. doi: 10.1097/AOG.0000000000004603.
7
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Front Immunol. 2021 Dec 9;12:790469. doi: 10.3389/fimmu.2021.790469. eCollection 2021.
8
Treatment of COVID-19 in high-risk outpatients.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):e1.
9
Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.
Ital J Pediatr. 2022 Jan 12;48(1):7. doi: 10.1186/s13052-021-01187-1.
10
Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
J Infect Public Health. 2024 Sep;17(9):102512. doi: 10.1016/j.jiph.2024.102512. Epub 2024 Aug 7.
引用本文的文献
1
COVID-19 infection in children with blood cancer: A systematic review.
Ann Hematol. 2025 Feb;104(2):1203-1230. doi: 10.1007/s00277-024-06057-4. Epub 2024 Nov 5.
2
Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care.
Viruses. 2024 Apr 26;16(5):690. doi: 10.3390/v16050690.
3
Neutralizing monoclonal antibodies for early treatment of hospital-acquired SARS-CoV-2 infection in hematologic patients.
EJHaem. 2022 Sep 2;3(4):1172-80. doi: 10.1002/jha2.554.
4
Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges.
Cancers (Basel). 2022 May 19;14(10):2494. doi: 10.3390/cancers14102494.
5
Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Curr Oncol. 2022 Mar 26;29(4):2312-2325. doi: 10.3390/curroncol29040188.
6
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Hematol Oncol. 2022 Apr;40(2):280-286. doi: 10.1002/hon.2974. Epub 2022 Feb 17.
本文引用的文献
1
Neutralizing Antibody Therapeutics for COVID-19.
Viruses. 2021 Apr 7;13(4):628. doi: 10.3390/v13040628.
2
Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review.
Pediatr Blood Cancer. 2021 Jun;68(6):e29005. doi: 10.1002/pbc.29005. Epub 2021 Mar 15.
3
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.
Cancer Cell. 2021 Feb 8;39(2):257-275.e6. doi: 10.1016/j.ccell.2021.01.001. Epub 2021 Jan 5.
4
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
Cell. 2020 Dec 23;183(7):1901-1912.e9. doi: 10.1016/j.cell.2020.10.049. Epub 2020 Nov 4.
5
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
6
Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
Antiviral Res. 2020 Sep;181:104880. doi: 10.1016/j.antiviral.2020.104880. Epub 2020 Jul 15.
Zotero 插件